Background: The aim of this study is to determine efficacy and feasibility of the combination regimen irinotecan and cisplatin in patients with cisplatin advanced penile cancer. ) administered every 28 days. Patients were treated either in the neo-adjuvant setting for T3 or N1-N2 disease with a maximum of four cycles before surgery or up to eight cycles for T4 or N3 or M1 disease. The study was designed with the aim to exclude a response rate (complete response + partial response) <30% (a = 10%, power = 95%).
introduction
The last decade has witnessed considerable progress with less morbidity caused by surgical treatment of penile carcinoma and the development of plastic surgery techniques for gland reconstruction [1] and sentinel node sampling [2] . In contrast, despite advances in other tumour types, with the development of novel more active and less toxic chemotherapy which are ideally suited to older patients such as those who develop penis cancer, there has been limited improvement of chemotherapy for penile cancer since the reports on the 5-fluorouracil (5-FU)-cisplatin [3] or methotrexate-bleomycin-cisplatin combinations [4] . The reported response rates were in the range of 25%-32.5% for both combinations, with limiting toxic effects for the latter. The most interesting advantage, however, is the high durable complete remission rate at 5 years obtained in patients with locally advanced nodal and soft tissue disease treated with neo-adjuvant chemotherapy and surgical removal of residual disease since it renders patients eligible for reconstruction with low morbidity [5] [6] [7] .
Prompted by reports of irinotecan being well tolerated in combination with csplatin [8] and synergizing with another platinum analogue in a variety of solid tumours [9] , the EORTC Genito-Urinary Tract Cancer Group set out to undertake a phase II study of this combination in penile cancer patients with locally advanced disease or recurrence after treatment of local disease.
patients and methods
This open, nonrandomised, prospective phase II study involved six centres belonging to the EORTC Genito-Urinary Tract Cancer Group. /l, platelet count ‡100 · 10 9 /l, total bilirubin £1.5 upper limit of normal (ULN) serum alanine aminotransferase, aspartate aminotransferase £2.5 ULN in the absence of liver metastases or £5 if there were liver metastases and adequate renal function with a glomerular filtration rate (GFR) ‡60 ml/mn. The GFR was to be either directly measured or calculated according to the Cockcroft and Gault formula.
A clinical history and physical examination with CT scan imaging of the abdomen, pelvis and thorax and blood tests were carried out within 14 days before inclusion. All patients gave their written informed consent, and the study was approved by an Ethics Committee in accordance with national standards of Good Clinical Practice. keeping with guidelines at each investigator site, to insure that adequate hydration was given. Patients were treated either in the neo-adjuvant setting for T3 or N1-N2 disease with a maximum of four cycles before surgery or up to 8 cycles for T4 or N3 or M+ distant metastatic disease.
supportive care
Antiemetic medication was that prescribed locally in routine practice. Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended.
dosage modifications
Treatment was administered on day 1 if the white blood cell count was ‡3 · 10 9 /l and the platelet count was ‡100 · 10 9 /l. The full dose of irinotecan was given on day 8 or 15 to patients with an ANC ‡1 · /l. If grade 3 diarrhoea occurred, irinotecan was withheld until recovery and if grade 4 diarrhoea occurred, irinotecan was discontinued. In the event of cholinergic syndrome, reported to occur with irinotecan, atropine (0.25 mg s.c.) was administered at a single dose. Treatment delays (of up to 2 weeks) were allowed.
safety and responses
The primary end point of the trial was the objective response to treatment, as defined by 'response evaluation criteria in solid tumors' criteria [11] .
Toxicity was graded according to the Common Toxicity Criteria version 3.0 [12] .
The tumour was re-evaluated every two cycles during treatment as well as at the end of chemotherapy and at least 4 weeks after the first observation of a complete or partial response. After discontinuation of protocol treatment, patients who had not progressed or had not undergone local treatment were re-evaluated every 8 weeks, unless they had started a new anticancer therapy.
study design
The statistical design aimed at excluding a response rate £30% with a power of 90% and a one-sided type I error rate of 10% using a two-stage Simon Optimum design [13] . Under those hypotheses, the total sample size required 28 eligible patients receiving at least one dose of treatment. The trial could have been discontinued if four or less objective responses were observed in the first 13 treated eligible patients. The secondary end points of the trial were the duration of response and tolerance of the drug combination.
results patient characteristics
Twenty-eight patients were included between May 2004 and January 2006 among whom seven in the neo-adjuvant setting. Two patients were ineligible, (one patient was >75 and another supposedly had metastatic mediastinal lymph nodes which were later histologically proven to be related to previously undiagnosed sarcoidosis instead of cancer).
The 28 treated patients were assessable for treatment administration and toxicity and 26 eligible patients were assessable for response. Baseline patient characteristics are summarised in Table 1 .
treatment administration
Treatment administration and modifications are summarised in Table 2 . Altogether, treatment was administered as planned with a median number of four cycles and a median relative dose intensity of 89.1% for irinotecan and 101.1% for cisplatin.
adverse events
Toxicity, summarised in Table 3 , was acceptable with only three cases of grade 3 diarrhoea and two cases of grade 4 neutropenic fever, all recovering rapidly. One patient with advanced disease stopped treatment after one cycle because of toxicity (pneumonia with grade 4 neutropenia).
response rates
The evaluation of response of the 26 eligible patients is summarised in Table 4 . Two complete and six partial responses were obtained. Two responses were observed among the seven patients treated in the neo-adjuvant setting versus six among the 19 assessable patients with advanced disease. However, three patients treated in the neo-adjuvant setting underwent a lymphadenectomy after chemotherapy and no evidence of malignancy was found at the pathological examination. The overall response rate was 30.8% (confidence interval 80% 18.8% to 45.1%) which does not statistically exclude that the true response rate may be >30% but the lower bound of the two-sided 80% confidence interval being 18.8% indicated that the study was negative.
discussion
Penile cancer is a relatively rare cancer worldwide, but less rare in Eastern Europe, parts of Africa, the West Indies and South America [14] . The epidemiology of penile cancer is known to be related to human papillomavirus (HPV) infection, previous long-lasting premalignant lesions, smoking habits and hygiene [15] . It is the first cancer for which a public health initiative, circumcision, has substantially reduced the risk, though not totally eliminated its occurrence [16] . Even when penile cancer occurs in countries where health care is readily available, it is most often diagnosed at an early stage where limited local treatments like conservative surgery, laser therapy or brachytherapy may be curative with function preservation [17] [18] [19] . It is against this background that the results of this study should be assessed. Indeed, the first reports of chemotherapy in advanced penile cancer are recent compared with those published in almost any other malignant disease. Furthermore, they were initially retrospective and concerned only a few patients [20] [21] [22] . The only possible conclusion then was that chemotherapy was potentially active in advanced penile cancer [7] . However, as soon as chemotherapy was used in advanced penile cancer, the adjuvant/neo-adjuvant strategy was explored since it appeared unlikely that chemotherapy alone could cure advanced disease [7] . WBC, white blood cell; ANC, absolute neutrophil count. original article
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Two trials reported on the bleomycin-methotrexatecisplatin combination. The first included 14 patients with squamous cell carcinoma of the genital tract, 12 of whom had a penile primary. Among the 14 patients, 11 were treated i.v. and the other three intra-arterially. A 72% overall response rate was reported [24] .
The second more recent study using the same combination with updated evaluation criteria reported a 32.5% response rate in 40 assessable patients with five treatmentrelated deaths [4] . It was concluded that toxicity was prodigious and that future research should focus on decreasing toxicity [4] .
The 5-FU-cisplatin combination was investigated in only a very small series of patients [3, 22] . In the most recent study, two of eight patients achieved a partial response (RR 25), both of whom required secondary local treatments to obtain a complete response [3] .
Although better tolerated than the bleomycin-methotrexatecisplatin combination, clearly, the irinotecan-cisplatin combination is no more active than its predecessors.
Although the study was underpowered for a subgroup analysis, the most interesting observation with a potential for future studies is the fact that three patients treated in the neo-adjuvant setting had a pathologically disease-free lymphadenectomy [3] . There is an increasing number of mainly small reports of similar results with combined modality treatment [5] [6] [7] . This suggests that further trials in patients with earlier disease, combining an organ-preserving approach, short chemotherapy courses and possibly HPV vaccination, may be a way to maximise benefits from all these components which, separately, show promise 25]. International collaboration will, however, be required to recruit sufficiently large patient cohorts in the neo-adjuvant setting with histological confirmation of response in all patients.
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